Brand Engagement Network joins Russell 3000 and Russell 2000 indexes

1 min read     Updated on 15 Jun 2026, 04:06 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Brand Engagement Network Inc. (NASDAQ: BNAI) has been added to the Russell 3000 and Russell 2000 indexes effective June 26, 2026, following the annual reconstitution based on market capitalization as of April 30. This inclusion places the company among approximately 3,000 of the largest U.S. public companies, potentially increasing its visibility to the $12.2 trillion in assets benchmarked to Russell U.S. indexes. CEO Tyler Luck highlighted the milestone as significant for the company's public journey while reaffirming its focus on AI solutions for regulated industries.

powered bylight_fuzz_icon
43065345

*this image is generated using AI for illustrative purposes only.

Brand Engagement Network Inc. (NASDAQ: BNAI) has been selected for membership in the Russell 3000 Index and the Russell 2000 Index, effective at the close of U.S. markets on June 26, 2026. The inclusion is part of the 2026 Russell U.S. Indexes reconstitution, which captures the largest U.S. stocks as of April 30 and ranks them by total market capitalization to determine index membership for the coming year. Approximately $12.2 trillion in assets are benchmarked to Russell U.S. indexes, a figure that underscores the significance of this addition for the company's visibility among institutional investors.

Membership in the Russell 3000 Index automatically results in inclusion in the Russell 2000 Index, along with applicable Russell style indexes. The Russell 3000 Index measures the performance of approximately 3,000 of the largest U.S. public companies and represents about 98% of the investable U.S. equity market. Russell indexes are widely used by investment managers and institutional investors for index funds and benchmarking purposes.

Strategic Implications

"Being added to the Russell indexes is a meaningful milestone for BEN and an important moment in our journey as a public company," said Tyler Luck, Chief Executive Officer of Brand Engagement Network. He emphasized that while inclusion enhances visibility within the investment community, the company's focus remains on powering the engagement layer of AI and delivering value for customers and shareholders.

Company Overview

Brand Engagement Network develops secure, enterprise-grade artificial intelligence solutions designed for organizations in healthcare, financial services, hospitality, and other regulated industries. The company's technology operates within secure, closed-loop enterprise environments using approved organizational data and built-in governance and compliance controls. BEN's proprietary Engagement Language Model (ELM) enables conversational AI interactions that connect human intent to organizational data, workflows, and real-world outcomes.

Index Key Metric Value
Russell 3000 Index Companies covered ~3,000
Russell 3000 Index Market representation ~98% of investable U.S. equity market
Russell U.S. Indexes Assets benchmarked $12.2 trillion
FTSE Russell Global Indexes Assets benchmarked $21.2 trillion

How will the anticipated passive inflow from index funds impact BNAI's trading volume and liquidity leading up to the June 26, 2026 rebalancing?

What specific metrics or milestones does BEN need to achieve to ensure it maintains a market capitalization sufficient to remain in the Russell 2000 beyond the 2027 reconstitution?

Will BEN leverage this increased institutional visibility to pursue secondary offerings or strategic partnerships within the healthcare and financial services sectors?

like19
dislike

Brand Engagement Network launches INTERVENT Health AI JV

2 min read     Updated on 11 Jun 2026, 04:23 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Brand Engagement Network and INTERVENT International have launched INTERVENT Health AI, a 50/50 joint venture combining BEN's conversational AI with INTERVENT's clinically validated methodologies. The JV targets global markets with BEN serving as the exclusive AI software provider in North America for five years.

powered bylight_fuzz_icon
42546475

*this image is generated using AI for illustrative purposes only.

Brand Engagement Network, Inc. (BEN) and INTERVENT International, LLC have launched INTERVENT Health AI, Inc., a 50/50 joint venture headquartered in Delaware, to develop and commercialize AI-powered health coaching solutions. The partnership combines BEN's conversational AI with INTERVENT's clinically validated methodologies and proprietary healthcare datasets. Unlike many AI healthcare applications relying on publicly available information, INTERVENT Health AI is built on more than 25 years of clinically validated health coaching methodologies designed to drive measurable behavior change and favorable long-term health outcomes. The joint venture aims to serve direct-to-consumer, employer, healthcare, and enterprise markets by leveraging clinical research datasets and telehealth coaching interactions involving more than 2,000,000 people.

According to information provided by INTERVENT, its programs have been used to serve more than two million individuals and are supported by more than 120 published scientific abstracts and manuscripts. These include studies conducted across more than 150 medical centers with funding from organizations such as the NIH, PCORI, and the Public Health Agency of Canada. Through INTERVENT Health AI, BEN's conversational AI is expected to help scale these evidence-based coaching systems to broader populations and new healthcare markets.

Key Terms and Governance

The joint venture agreement establishes a Board of Directors comprising one appointee from BEN, one from INTERVENT, and one mutually agreed independent director. The capital structure authorizes 100,000,000 shares of Class A Common Stock and 10,000,000 shares of Class B Preferred Stock. BEN and INTERVENT each received 32,500,000 shares of Class A Common Stock, representing 50% of the issued and outstanding common equity. An additional 30,000,000 Class A shares were reserved for future issuance, and 5,000,000 shares were reserved for a long-term incentive plan. Each founding shareholder also received 5,000,000 shares of Class B Preferred Stock, valued at $1.00 per share, as consideration for pre-paid intellectual property licenses.

Commercial Arrangements

INTERVENT Health AI has entered into an exclusive five-year North American commercialization and technology development agreement with SKYE AI USA, LLC, a wholly owned subsidiary of BEN. This arrangement is subject to agreed performance milestones. BEN, through SKYE, is entitled to receive 35% of certain revenues generated by INTERVENT Health AI from software, services, and commercialization activities under this North American arrangement, net of agreed commissions and third-party fees. Additionally, BEN has agreed in principle to a Reseller and Services Agreement, appointing it as the exclusive provider of AI platform development, training, and deployment services for INTERVENT Health AI in North America for an initial five-year term.

International Expansion

The joint venture has also agreed to material terms for non-exclusive international reseller arrangements. These arrangements will facilitate the commercialization of INTERVENT Health AI services through BEN-affiliated entities in Latin America and Africa. Under these proposed agreements, INTERVENT Health AI is expected to receive 50% of gross revenues generated from such sales, after the deduction of agreed commissions and business development expenses.

Share Class Authorized Shares Issued to BEN Issued to INTERVENT Reserved/Other
Class A Common Stock 100,000,000 32,500,000 32,500,000 35,000,000
Class B Preferred Stock 10,000,000 5,000,000 5,000,000 0

The Shareholder Agreement includes customary governance provisions, pre-emptive rights, and ownership protection, including restrictions on issuances that would reduce either founding shareholder below specified ownership thresholds without approval.

What specific performance milestones must INTERVENT Health AI achieve to maintain the exclusive five-year commercialization agreement with SKYE AI USA?

How will the joint venture leverage the 30,000,000 reserved Class A shares to fund future growth or attract strategic investors?

What is the projected timeline for rolling out INTERVENT Health AI services in Latin America and Africa under the non-exclusive international reseller arrangements?

like16
dislike